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BILAGAbstract Aim of the work: To evaluate the impact of systemic lupus erythematosus (SLE) on
urinary levels of podocalyxin and nephrin and to determine their relationship to renal biopsy
and disease activity in lupus nephritis (LN) patients.
Patients and methods: The study included 50 LN patients with their renal biopsy classiﬁed
according to the international society of nephrology. Disease activity was determined using the
British Isles Lupus Assessment Group (BILAG). All patients underwent clinical and laboratory
evaluation. Urine samples were collected for the assessment of urinary podocalyxin (UPx) and
nephrin (UN) by ELISA and for the estimation of protein (UP) and creatinine (Cr) concentrations.
The UPx:Cr, UN:Cr and UP:Cr ratios were calculated.
Results: Urinary levels of podocalyxin (593.8 ± 282.2 ng/ml), nephrin (304.1 ± 236.8 ng/ml)
and protein (2.36 ± 0.56 g/l) were signiﬁcantly higher, while urinary creatinine levels (101.4
± 28.7 mg/l) lower in LN patients compared to control (38.1 ± 9 ng/ml, 19.2 ± 4.1 ng/ml, 0.34
± 0.13 g/l and 155.4 ± 26.7 mg/l; p= 0.0008, p= 0.0003, p= 0.00002 and 0.0009, respectively).
Consequently, UNCr, UPxCr and UPCr ratios were signiﬁcantly higher in patients compared to
control. There was a signiﬁcant correlation of the estimated ratios with the LN class and with
the BILAG scores being most signiﬁcant with UPx:Cr ratio. ROC curve and regression analyses
deﬁned UPx:Cr ratio as the speciﬁc signiﬁcant predictor of pathological LN grade.
Conclusion: SLE deleteriously affects ﬁne glomerular structure as reﬂected by increased urinary
levels of podocyte-related proteins; podocalyxin and nephrin. Urinary podocalyxin/creatinine ratio
178 A.T. Abou Ghanima et al.signiﬁcantly predicts the pathological impact of SLE on the kidney and could be used as a non-
invasive marker for such effect and its progression.
 2015 The Authors. Publishing services provided by Elsevier B.V. on behalf of Egyptian Society of
Rheumatic Diseases. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Systemic lupus erythematosus (SLE) is an inﬂammatory
autoimmune disease characterized by the production of antin-
uclear antibodies [1]. Lupus nephritis (LN) patients present
with proteinuria that has generally been associated with
immune complex deposition in the glomerular capillary wall
and endo-capillary proliferation and inﬂammation [1]. Many
studies focused on the importance of ﬁnding potential
biomarkers, to estimate the degree of LN in SLE patients, such
as serum cystatin C and urinary neutrophil gelatinase-
associated lipocalin [2], cytokines [3], markers of oxidative
stress [4], matrix metalloproteinase [5], adipokines [6,7] and
growth arrest speciﬁc protein 6 [8]. The search for reliable
easily measured markers is still necessary and ongoing.
Podocytes are highly differentiated glomerular epithelial
cells that line the outside of the glomerular capillary with
foot processes linked to the glomerular basement membrane
with their actin cytoskeleton [9]. The foot processes form a
characteristic inter-digitating pattern leaving ﬁltration slits
in-between. Integrity of this ﬁltration barrier is important
in order to prevent the loss of protein into the urine [10].
Podocyte injury is an important feature of several renal dis-
eases. Regulation of the podocyte actin cytoskeleton is of
critical importance for sustained function of the glomerular
ﬁlter and is mediated by several podocyte proteins such as
nephrin and podocin [11,12]. Several markers of podocyte
injury include nephrin, synaptopodin, podocalyxin and
podocin [13,14]. The relationship between urinary podocyte
protein and renal diseases is supported by their detection
in patients with immunoglobulin A nephropathy, Henoch–
Scho¨nlein purpura nephritis, lupus nephritis, diabetic
nephropathy and focal segmental glomerulosclerosis. The
detection of urinary markers of podocyte injury would
have broad implications for the evaluation of disease activ-
ity, the degree of dedifferentiation and the possibility of
podocyte regeneration [15].
The aim of the current study was to evaluate the impact of
SLE on ﬁne glomerular architecture using podocyte injury
related markers; podocalyxin and nephrin in urine and to
determine their relationship to pathological classes of renal
biopsy and disease activity.
2. Patients and methods
This study was conducted at Rheumatology, Internal Medicine
and Clinical Pathology departments, Dallah and Ibn Sina
College Hospitals, Kingdom of Saudi Arabia (KSA). The
study included 50 lupus nephritis (LN) patients diagnosed by
previous renal biopsy. The research protocol was approved
by the Ethics Committee of our hospitals and informed written
consents were obtained from all participants. Systemic lupus
erythematosus (SLE) was diagnosed according to the systemiclupus international collaborating clinics (SLICC) classiﬁcation
criteria for SLE [16]. All patients underwent full clinical
examination and laboratory tests were performed including
complete blood count (CBC), C-reactive protein (CRP),
complement (C3 and C4), anti-nuclear antibodies (ANA)
and anti-double stranded deoxyribonucleic acid (anti-
dsDNA). Anemia was deﬁned by a hemoglobin (Hb) concen-
tration of 612 g/dl for women and of 613.5 g/dl for men
[17]. Proteinuria was measured by a dipstick method. The
study also included 20 matched normal subjects free of renal
disease as control group for estimated urinary biomarkers.
Disease activity was determined using the British Isles
Lupus Assessment Group (BILAG) score which consisted of
evaluation of 8 points of interest: general, muco-cutaneous,
neurological, musculoskeletal, cardio-respiratory and renal
manifestations, vasculitis and hematological ﬁndings. To
obtain a global score, BILAG component scores are assigned
numerical values: A= 9 (most active disease), B= 3 (interme-
diate activity), C= 1 (mild, stable disease activity), D= 0
(inactive disease) and E= 0 (no activity), resulting in a poten-
tial summed range of 0–72 points with 72 = most active dis-
ease affecting the 8 organs [18].
Lupus nephritis was diagnosed depending on the presence
of proteinuria and hematuria [19] and renal biopsy
histopathology was classiﬁed according to the International
Society of Nephrology/Renal Pathology Section (ISN/RPS)
classiﬁcation as minimal mesangial (class I), mesangial prolif-
erative LN (class II), focal LN (class III), diffuse LN (class
IV), membranous LN (class V) and advanced sclerosis (class
VI) [20].2.1. Urine sample collection
Urine (10 ml) was collected in plastic tubes, without preserva-
tive. Samples were clariﬁed by centrifugation at 3.000 rpm for
5 min and supernatant collected in Eppendorf tubes and kept
frozen at 80 C till assayed for:
(1) Urine protein concentrations were measured by the Brad-
ford method [21].
(2) Estimation of urinary markers of podocyte injury: urinary
podocalyxin and urinary nephrin was estimated using
commercially available ELISA kits (Exocell Inc.,
Philadelphia, PA). Urine samples were diluted with dilu-
tion buffer provided by the ELISA kits in a ratio of 1:2
for urinary podocalyxin [9] and 1:1 for Urinary nephrin
[22]. Each sample was measured in duplicate. The values
are expressed as ng/ml.
(3) Urine creatinine was measured by the Jaffe reaction on
the same aliquot of urine to [27] adjust the ratio of uri-
nary podocalyxin to creatinine (UPx:Cr), urinary
nephrin to creatinine (UN:Cr) and urine total protein-
to-creatinine ratio (UP:Cr).
1792.2. Statistical analysis
Table 2 Disease activity as assessed by the British Isles Lupus
Assessment Group (BILAG) grading in lupus nephritis
patients.
BILAG BILAG grade
Manifestations A B C D E
General 5 8 13 15 9
Mucocutaneous 6 12 20 7 5
Neurological 3 10 11 17 9
Musculoskeletal 3 8 29 6 4
Cardiorespiratory 3 12 23 7 5
Renal 7 18 19 4 2
Vasculitis 10 13 10 11 6
Hematological 11 12 16 7 4
BILAG: British Isles Lupus Assessment Group. BILAG grades: A:
severe = 9, B: intermediate = 3, C: mild = 1, D: inactive = 0, E:
no activity = 0.Obtained data were presented as mean ± SD, ranges, numbers
and ratios. Results were analyzed using Wilcoxon; ranked test
for unrelated data (Z-test) and Chi-square test (X2 test). Sensi-
tivity and speciﬁcity of estimated parameters as predictors were
evaluated using the receiver operating characteristic (ROC)
curve analysis judged by the area under the curve (AUC) com-
pared versus the null hypothesis that AUC= 0.05. Regression
analysis (Stepwise method) was used for stratiﬁcation of stud-
ied parameters as speciﬁc predictors. Statistical analysis was
conducted using the SPSS (Version 15) for Windows statistical
package. p value < 0.05 was considered statistically signiﬁcant.
3. Results
The current study included 50 SLE patients; 39 females and 11
males (F:M 3.5:1) with a mean age of 45.7 ± 11.8 years (range:
22–69 years) and a mean disease duration of 5.1 ± 1.1 years
(range: 3–8 years). In our clinics, there is high number of males
for regular follow up so the number of males in our study was
relatively high and there was no effect of gender on levels of
the study parameters. All patients had LN diagnosed clinically
and documented by renal biopsy that showed varied classes
with focal LN being the most frequent. Details of patients’ dis-
tribution according to results of renal biopsy are shown in
Table 1. Mean BILAG score was 17 ± 9.6 (range: 8–38).
The BILAG score ranged from 8–10 in 24 patients; 11–17 in
6; 20–29 in 13 and 32–38 in 7 patients. Systematic BILAG
grading is shown in Table 2.
Hemogram detected 11 anemic patients (22%) with a mean
Hb concentration of 10 ± 1.2 gm/dl, while it was 13.2
± 0.5 gm/dl in the other 39 patients. The total leukocytic count
(TLC) was 8.25 ± 2.7  103/dl, platelet count 165 ± 18.6 
103/dl, erythrocyte sedimentation rate (ESR) 41 ±
15.6 mm/1st h, CRP 7.2 ± 4.6 mg/dl, Complement C3 94
± 53.4 mg/dl, C4 60.4 ± 39.3 mg/dl, the ANA was positive
in 100% of patients and the anti-ds DNA was 216.8
± 99.2 U/l.
Urinary levels of nephrin, podocalyxin and protein were
signiﬁcantly higher in LN patients compared to controls, while
urinary creatinine levels were signiﬁcantly lower compared to
control levels. Consequently, urinary nephrin/creatine
(UNCr), urinary podocalyxin/protein (UPxCr) and urinary
protein/creatinine (UPCr) ratios are signiﬁcantly higher in
studied patients compared to control levels (Table 3).
Biomarkers in lupus nephritis patientsTable 1 Renal biopsy classiﬁcation in lupus nephritis
patients.
Renal biopsy classiﬁcation in LN patients Number (%)
ISN/RPS I Minimal mesangial LN 9 (18)
II Mesangial proliferative LN 16 (32)
III Focal LN 18 (36)
IV Diﬀuse LN 3 (6)
V Membranous LN 3 (6)
VI Advanced sclerosis 1 (2)
ISN/RPS: International Society of Nephrology/Renal Pathology
Section, LN: lupus nephritis.A stepwise increase of estimated ratios with increased
pathological disease severity grade was found (Fig. 1). The
UPx:Cr ratio signiﬁcantly correlated with the UN:Cr ratio
(r= 0.43, p= 0.002), UP:Cr ratio (r= 0.37, p= 0.008),
BILAG score (r= 0.31, p= 0.03) and with the LN class
(r= 0.56, p= 0.0008). The UN:Cr ratio signiﬁcantly corre-
lated with the UP:Cr ratio (r= 0.31, p= 0.037), BILAG score
(r= 0.29, p= 0.04) and with the LN renal biopsy class
(r= 0.38, p= 0.007). The UP:Cr signiﬁcantly correlated with
the BILAG score (r= 0.28, p= 0.046) and with the renal
biopsy class (r= 0.36, p= 0.009). The renal biopsy grading
signiﬁcantly correlated with the BILAG scores (r= 0.29,
p= 0.04).
In a trial to determine a predictor for pathological LN dis-
ease severity, UPxCr ratio showed the highest AUC using
ROC curve analysis that was the only signiﬁcant area versus
the null hypothesis (Table 4, Fig. 2). Regression analysis
deﬁned UPxCr ratio as the speciﬁc signiﬁcant predictor of
pathological grade, while UP:Cr ratio and BILAG scoring
were non-signiﬁcant predictors as shown in Table 4.
4. Discussion
The current study detected elevated urinary levels of podoca-
lyxin (UPx) and nephrin (UN) and their relative concentration
to urinary creatinine (Cr) level in LN patients compared to
normal control subjects. These ﬁndings indicated the impactTable 3 Urinary podocalyxin, nephrin and protein and their
ratios relative to urinary creatinine level in lupus nephritis
patients and control.
Urinary parameter
mean ± SD
LN patients
(n= 50)
Control
(n= 20)
p
Podocalyxin (ng/ml) 593.8 ± 282.2 38.1 ± 9 0.00008
Nephrin (ng/ml) 304.1 ± 236.8 19.2 ± 4.1 0.0003
Protein (g/l) 2.36 ± 0.56 0.34 ± 0.13 0.00002
Creatinine (mg/l) 101.4 ± 28.7 155.4 ± 26.7 0.0009
Nephrin:creatinine 287.4 ± 163.3 12.7 ± 3.2 0.0001
Podocalyxin:creatinine 602 ± 284.5 25 ± 6.5 0.00001
Protein:creatinine 2.46 ± 0.72 0.23 ± 0.09 0.00001
LN: lupus nephritis.
Figure 1 A: urinary podocalyxin:creatinine (UPx:Cr), B: urinary neprin:creatinine (UN:Cr), C: urinary protein:creatinine (UP:Cr) ratios
in lupus nephritis patients according to the renal biopsy classes and in control.
Figure 2 ROC curve analysis of the ratios of urinary podoca-
lyxin, nephrin and protein relative to urinary creatinine level and
British Isles Lupus Assessment Group (BILAG) scoring as
predictors for International Society of Nephrology (ISN) renal
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Cr ratios showed signiﬁcant correlations with pathological
changes in lupus nephritis more than other evaluated parame-
ters like those related to podocytes alone [23].
The obtained results showed a signiﬁcant correlation
between both UPx:Cr ratio and UN:Cr ratios with the BILAG
disease activity scores and UP:Cr ratio but no signiﬁcant cor-
relation between disease duration and the BILAG score. More
interestingly, both UPx:Cr ratio and UN:Cr ratios showed a
signiﬁcant correlation with the ISN renal biopsy grade. The
UPx:Cr ratio was found to be a signiﬁcant predictor for renal
pathological class thus it could be considered as a potential
non-invasive biomarker for the grade of LN. This was in
agreement to the results presented by Perysinaki et al. [24]
reporting that glomerular expression of nephrin and podocin
signiﬁcantly correlated with and became pronounced at
advanced renal biopsy histopathological classes (focal and dif-
fuse proliferative LN). The expression of nephrin and podocin
was reduced in early stages of LN (mesangial) and nephrin was
also particularly reduced in diffuse proliferative LN. Similarly,
Bollain-Y-Goytia et al. [25] reported that in LN patients,
reduction of glomerular podocytes signiﬁcantly correlated with
the cumulative excretion of urinary podocytes and proteinuria.
In line with the obtained results, Sabino et al. [23] reportedTable 4 Receiver operating characteristic (ROC) curve and
regression analysis of the ratios of estimated urinary
parameters relative to urinary creatinine level and British Isles
Lupus Assessment Group (BILAG) clinical scoring as
predictors for International Society of Nephrology (ISN)
pathological grading in lupus nephritis patients.
Predictors for ISN grading in LN patients (n= 50)
AUC CI p
ROC curve BILAG score 0.28 0.14–432 0.21
UPx:Cr 0.88 0.79–0.97 0.03
UN:Cr 0.68 0.3–1.06 0.31
UP:Cr 0.63 0.49–0.78 0.45
b t p
Regression UN:Cr 0.35 3.15 0.003
UPx:Cr 0.54 4.86 0.0007
ISN: International Society of Nephrology, LN: lupus nephritis,
AUC: Area under curve; CI: conﬁdence interval, b: Standardized
coefﬁcient. UPx:Cr: urinary podocalyxin:creatinine, UN:Cr: uri-
nary neprin:creatinine, UP:Cr: urinary protein:creatinine. Bold
values are signiﬁcant at p< 0.05.
biopsy pathological grading in lupus nephritis patients.that podocyturia correlated with the protein/creatinine ratio
and both showed a signiﬁcant correlation with the degree of
lupus disease activity. They concluded that podocyturia with
anti-podocin could be useful in monitoring disease activity in
LN patients. Wang et al. [26] reported that podocyte damage
was common in LN; urinary podocytes met the histological
criteria of lupus podocytopathy. Pure lupus podocytopathy
might act as an extreme form of lupus podocyte lesion, and
more patients might present with severe podocyte effacement
concealed in different types of LN. Sir Elkhatim et al. [27] doc-
umented that urine podocyte-related protein markers have
been used with varying degrees of success to study glomerular
diseases and the determination of urinary podocyte loss may
become an important noninvasive tool in the evaluation of
glomerular diseases. Rezende et al. [28] reported that in prolif-
erative forms of LN there seems to occur structural podocyte
damage, whereas in the pure membranous forms the predom-
inant preserved pattern suggests a dysfunctional podocyte
lesion that may account for the better long-term prognosis of
proteinuria outcome.
Biomarkers in lupus nephritis patients 181The present study relied on the detection of podocyte-
related markers using ELISA estimation of their urinary levels.
Review of the literature detected that previous studies used
ELISA estimation of urinary podocalyxin and nephrin in other
kidney diseases, wherein Hara et al. [29] quantiﬁed urinary
podocalyxin by ELISA in patients with glomerular diseases
and patients with type 2 diabetes and found that levels of uri-
nary podocalyxin were elevated in patients with various
glomerular diseases and patients with diabetes. Also, Palacios
de Franco et al. [30] reported signiﬁcantly higher levels of uri-
nary podocalyxin as measured using by ELISA in preeclamp-
sia/eclampsia. Recently, in 2015, Wang et al. [31] using indirect
immunoﬂuorescence, ELISA and Western blotting of urinary
sediment found that urinary podocyte number and nephrin
level were signiﬁcantly higher in patients with LN compared
to patients with other glomerular diseases and were higher in
patients with severe proteinuria and urinary nephrin expres-
sion was related to podocyte and urinary albumin/creatinine
ratio. Moreover, they found that urinary podocyte number
and nephrin level dramatically increased in the focal segmental
glomerulosclerosis group as compared to those of the mesan-
gial proliferative glomerulonephritis and minimal change dis-
ease groups and concluded that the detection of the urinary
podocytes and nephrin could be taken as non-invasive markers
for glomerular disease severity.
It could be concluded that SLE deleteriously affects the ﬁne
glomerular structure as reﬂected by increased urinary levels of
podocyte-related proteins; podocalyxin and nephrin. Urinary
podocalyxin/creatinine ratio signiﬁcantly predicts the patho-
logical impact of SLE on the kidney and could be used as a
non-invasive marker for such effect and its progression. A lon-
gitudinal larger scale study is recommended to further assess
the value of these markers in response to therapy.
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